2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 179

Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 788

Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 552

Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 800

Measurement of Serum Cytokines during the Apparent Remission State of Takayasu Arteritis – What Do Cytokines Tell Us?

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 338

Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 763

Mechanisms of Insulin-like Growth Factor-II-Mediated Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 449

Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 97

Medical Student Interest in Rheumatology As a Career

Education Poster

9:00AM-11:00AM: Abstract Number: 473

Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 670

Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 284

Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 15

Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 493

Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 443

Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 446

Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].